(UroToday.com) The 2025 European Society for Medical Oncology (ESMO) Annual Congress was host to a radioligand therapeutics proffered paper session. Dr. Karolien Goffin discussed the previously ...

(UroToday.com) The 2025 SNMMI annual meeting featured a prostate cancer session and a presentation by Dr. Adrien Holzgreve discussing a clinical trial protocol update of FLEX-MRT, a randomized phase 2 ...

(UroToday.com) The 2025 ESMO annual meeting featured a biomarker-based personalization in metastatic prostate cancer session and a presentation by Dr. Alice Bernard-Tessier discussing targeting ...

Phase III Evaluation of Mevrometostat + Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (MEVPRO-1 & MEVPRO-2) A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.